Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of ...
Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback